✅ 8 criteria passed
❌ 3 criteria to solve
Boost xconomy.com's SEO with Kontactr's Guest Posting.
Secure high-authority, do-follow backlinks from our trusted site—DA45 domain authority and PA55 homepage and blog pages.
Perfect for webmasters seeking higher search rankings and increased organic traffic.
Simple, quick, and effective.
opens a new window
Xconomy | Business, Life Sciences, and Technology News
https://xconomy.com
Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, close-to-the-scene information about...
https://xconomy.com
Xconomy | Business, Life Sciences, and Technology News
Xconomy is a national news and events company dedicated to providing tech and biotech business leaders with timely, insightful, cl...
Great, a redirect is in place to redirect traffic from your non-preferred domain. All versions of your page point to the same URL.
ⓘ The results of our semantic analysis are shown below using the website's language.
They are the main concepts covered by xconomy.com.
Each concept has a confidence score. The higher it is, the more important the topic is relative to the page.
Topics | |
Xconomy Confidence: 84%
|
|
Biotechnology Confidence: 71%
|
|
Business Confidence: 68%
|
|
Information Confidence: 67% | |
Leadership Confidence: 66% |
❌ xconomy.com website speed is slow. Page speed is important for visitors and search engines.
Get insights to improve your page loading time.
This domain loads at the median speed of 1.1 seconds.
xconomy.com is faster than approximately 74 percent of the web. Your website page speed needs to be as fast as you can make it, without compromising the customer experience.
A good goal to achieve is a loading time of 2 seconds on desktop and mobile devices.
ⓘ This website is ranked #96.528 by Alexa.
This rank is traffic based. The lower the rank is, the better the domain is ranked.
Country | Rank |
United States of America | #33.645 |
India | #80.526 |
Mobile Rendering
This website doesn't seem to be optimized for Mobile Visitors.
Phone
Tablet
A good text to HTML ratio is anywhere from 25 to 70%.
This percentage refers to the visible text ratio, as opposed to HTML elements, image tags and other non-visible information.
Great, we found headings on this page.
For a better readability, only the first 20 <H1> tags are shown below.
Top level heading |
Xconomy national |
Aziz gilani |
Carol gallagher |
Andreas sundquist |
Ben elowitz (2) |
Chris rizik |
Brooks bell |
Benjamin cravatt |
Alan frazier |
Triplet therapeutics unveils $59m to try hairpin fix for huntington’s |
Amarin’s fish-oil pill wins fda nod to cut heart attack, stroke risk |
Bio roundup: sarepta’s approval, merck m&a, drug price bill & more |
ın an about-face, fda approves second sarepta muscular dystrophy drug |
Aı can unlock health data’s potential, but access ıs still difficult (2) |
Acadia names subbiah chief medical officer, head of medical affairs |
Ferring and blackstone team up to fund gene therapy firm with $570m |
Biotech roundup: gottlieb v. juul, solid slumps, avidity gets $100m & more |
David johnson |
David broecker |
Alan saltiel |
For a better readability, only the first 20 <H2> tags are shown below.
2nd level heading |
Triplet therapeutics unveils $59m to try hairpin fix for huntington’s |
Organovo’s demise offers path for tarveda to join the public markets |
Wave stock crashes after decision to halt duchenne drug studies |
Cell reprogramming startup bit bio ınks pact with charles river |
Axsome’s depression drug meets phase 3 goals, fda filing planned |
Building a better 3d bioprinter: ge healthcare and asls combine tech |
Amarin’s fish-oil pill wins fda nod to cut heart attack, stroke risk |
Bio roundup: sarepta’s approval, merck m&a, drug price bill & more |
ın an about-face, fda approves second sarepta muscular dystrophy drug |
Miragen restructures to focus on fibrosis, ınks $20m stock deal |
Amgen’s osteoporosis drug wins european nod, with a heart warning |
Aspen neuro bags $6.5m to test parkinson’s disease stem cell therapy |
ıterum’s antibiotic for super bugs falls short in phase 3, shares sink |
Flagship’s cellarity aims to advance cell behavior-based therapeutics |
Kalvista pharma eye drug partnered with merck flunks phase 2 test |
Zentalis steps out with $147m raised to develop “tried and true” small molecules |
Scripps research, abbvie expand drug discovery deal beyond cancer |
Perceptive unveils new $210m fund to ınvest in early-stage biotechs |
Eying cancer combos, sanofi to splash out $2.5b on san diego’s synthorx |
Aurinia plans fda filing after lupus nephritis drug hits phase 3 goals |
3rd level heading |
Top stories |
Latest posts |
Xconomist forumexpert ınsight and opinion |
Cleantech |
Healthtech |
Startups |
Life sciences |
Deals |
ıt |
People |
Energy |
Meet the xconomists |
Connect with xconomy |
Xconomy on demand |
4th level heading |
Underwriters and partners |
For a better readability, only the first 20 <H5> tags are shown below.
5th level heading |
Frank vinluan12/17/19 |
Sarah de crescenzo12/16/19 |
Melissa fassbender12/16/19 (3) |
Frank vinluan12/16/19 |
Sarah de crescenzo12/13/19 (2) |
Frank vinluan12/13/19 |
Frank vinluan12/12/19 (2) |
Sarah de crescenzo12/12/19 |
Frank vinluan12/11/19 |
Sarah de crescenzo12/11/19 |
Frank vinluan12/10/19 (2) |
Melissa fassbender12/10/19 |
Sarah de crescenzo12/10/19 |
Sarah de crescenzo12/9/19 |
Melissa fassbender12/9/19 (2) |
Frank vinluan12/9/19 |
Sarah de crescenzo12/6/19 (3) |
Frank vinluan12/6/19 |
Sarah de crescenzo12/5/19 (2) |
Frank vinluan12/5/19 (2) |
For a better readability, only the first 20 <H6> tags are shown below.
6th level heading |
Fetch rewards grabs $25m, plans to double staff as growth accelerates |
Nuance spinout cerence vies with tech giants in voice-aı for auto |
Can ford’s self-driving car business ımprove austin’s traffic woes? |
John halamka, livongo health & aı progress at x·con on oct. 22 |
As more grocers embrace tech, swiftly snags $15m to launch in seattle |
Triplet therapeutics unveils $59m to try hairpin fix for huntington’s (2) |
Organovo’s demise offers path for tarveda to join the public markets (2) |
Wave stock crashes after decision to halt duchenne drug studies |
Cell reprogramming startup bit bio ınks pact with charles river |
Axsome’s depression drug meets phase 3 goals, fda filing planned (2) |
Miragen restructures to focus on fibrosis, ınks $20m stock deal |
Stryker adds to trauma & extremities biz with $4b wright medical deal |
Eli lilly drug acquired in armo deal fails pancreatic cancer test |
Dova pharmaceuticals agrees to sobi acquisition, shares jump 38% |
Bridgebio pharma onboards eli wallace to lead oncology programs |
A safer crıspr? cyrus, broad ınstitute look to quell concerns |
Reata’s kidney drug hits goals of key study, paves way for fda filing |
Aı can unlock health data's potential, but access ıs still difficult |
Slideshow: nathan myhrvold’s food photography obsession on display |
Relay therapeutics names ben wolf chief medical officer |
We found 182 images on this website.
15
ALT attributes are missing on your image tags.
Alternative text allows you to add a description to an image.
Google rely on alternative text attributes to determine relevance to a search query. Alternative text also makes an image more likely to appear in a Google image search.
It looks like you're missing alternative text for 15 images on xconomy.com. Check your website to make sure it's specified for each image on the page.
18 of which have the nofollow attribute, meaning that their destination should not be afforded any additional weight or ranking by search engines.
For a better readability, only the first 50 internal links are shown below.
ⓘ Domain Registrar | SAFENAMES LTD |
ⓘ Registration Date | 08/25/2006 18 years, 2 months, 12 days ago |
ⓘ Last Modified | 08/26/2019 5 years, 2 months, 12 days ago |
ⓘ Expiration Date | 08/25/2020 Expired |
Host | IP Address | Country |
james.ns.cloudflare.com | 173.245.59.178 | United States |
marge.ns.cloudflare.com | 173.245.58.191 | United States |
SOCIAL MEDIA PRESENCE
You're doing quiet good on social media!
Social shares are a key signal, among many others, that search engines use to evaluate the rankings of a website. Asking people to share your pages, adding visible social share buttons and make great quality content are 3 of the most powerful ways to grow your social presence.